Skip to main content

Table 1 Clinical and biological characteristics of the study population at baseline

From: Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

Characteristics N = 107
Age (years) 56.6 ± 13.5
Disease duration (years) 9.9 ± 8.1
Gender (M/F) 29 (27.1)/78 (72.9)
DAS28-ESR 4.93 ± 1.3
Extra articular manifestations
 Nodules 18 (16.8)
 Sicca syndrome 15 (14)
 Vasculitis 2 (1.8)
X-ray erosions
 Presence 68 (66.6)
 Absence 34 (33.3)
 ND 5 (4.6)
 csDMARDs 77 (71.9)
 MTX 66 (61.7)
 LEF 10 (9.3)
 SLZ 0
 HCQ 1 (0.9)
 Glucocorticoids 74 (69.2)
 Dosage (mg/day) 6.8
 Previous bDMARDs 69 (64.5)
 TNFi 67 (62.6)
 Rituximab 5 (4.6)
 Abatacept 13 (12.1)
 Anakinra 1 (0.9)
 Rheumatoid factors 81 (75.7)
 Anti-CCP antibodies 82 (76.6)
CV risk factor:
 Hypertension 40 (37.3)
 Diabetes# 7 (6.5)
 Dyslipidaemia## 19 (17.7)
Smoking
 Never 65 (60.1)
 Previous 20 (18.7)
 Current 22 (20.5)
  1. Results are given as mean ± SD or N (%)
  2. M male, F female, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, bDMARDs biological disease-modifying anti-rheumatic drugs, TNFi TNFalpha inhibitor, MTX methotrexate, LEF leflunomide, SLZ sulfasalazine, HCQ hydroxychloroquine, ND not determined
  3. #Diabetes treatments: insulin N = 2, metformin N = 6, repaglinide N = 2, liraglutide N = 1, glicazide N = 1, sitagliptin N = 1
  4. ##Dyslipidaemia treatments: statins N = 14, ezetimibe N = 3, fibrates N = 2
\